Gu Qi Wang, PhD
Research Faculty, Pharmacology/Drug Development Group
Research The Liver-Biliary-Pancreatic Center
Carolinas Medical Center
Prior Positions and Experience
|2005 – 2007||Post-doctoral Research Associate, Faculty of Medicine, University of Manitoba (Winnipeg, Manitoba, Canada)|
|2005||Post-doctoral Fellow, University of Texas Health Science Center (San Antonio)|
|1992 – 2002||Research Assistant/Associate, Dept. of Pharmacology and Therapeutics, Faculty of Medicine, and Faculty of Pharmacy, University of Manitoba (Winnipeg, Manitoba, Canada)|
|1982 – 1992||Instructor/Lecturer, Dept. of Chemistry, and Dept. of Food Science, Nanchang University (Nanchang, China)|
PhD: 2005, University of Manitoba (Winnipeg, Manitoba, Canada)
BS: 1982, Nanchang University (Nanchang, China)
Role of liver fatty acid binding protein (L-FABP) in health and diseases
We have done some fundamental works on the cyto-protective function of L-FABP. We also noticed that L-FABP has a similar binding spectrum with G-protein coupled receptors and many transcription factors including PPARs, liver X receptors, and hepatocyte nuclear factor. L-FABP may be targeted for metabolic activation through the cross-talk of these transcription factors and their ligands. It would be helpful to consider the cellular delivery system that function to transport drugs to their target sites during drug design.
Development of nitric oxide therapy for muscular diseases
Nitric oxide (NO) mediates activation of satellite precursor cells which provides new precursor cells for skeletal muscle growth and muscle repair from injury or disease. Additionally, NO negatively regulates the ubiquitin-proteasome pathway, thereby decreasing the rate of degradation of muscle proteins. By developing a system to deliver NO to skeletal muscle and thereby manipulating the regulation of satellite cell activation, a treatment to promote and sustain muscle growth and repair will be found. The research will extend the understanding of the outcomes of that treatment in normal and dystrophic muscle, and will lead directly to the development of new therapies for a) conditions such as muscle atrophy in disuse and aging, and b) for the promotion of muscle tissue repair as required after injury or c) in neuromuscular diseases such as the muscular dystrophies.
Other research activities Dr. Wang’s group are the cellular drug uptake process in normal and diseased organs. The research goal is to enhance the efficiency of drug treatment. They have been investigating the uptake process of lipophilic drugs and the influence of extra- and intracellular binding proteins on uptake and intracellular transport.
Wang GQ and Lu QL. A nitrate ester of sedative alkyl alcohol improves muscle function and structure in a murine model of Duchenne muscular dystrophy. Mol Pharm. 2013, 10 (10):3862–3870. [PMID: 23924275]
Zhang LY, Wang GQ, Hou WH, Li P, Dulin A, Bonkovsky HL. Contemporary Clinical Research of Traditional Chinese Medicines for Chronic Hepatitis B in China: An Analytical Review. Hepatology. 2010; 51:690-698. [PMID: 20101751]
Wang GQ, Burczynski FJ, Hasinoff BB, Zhang K, Lu Q, Anderson JE. Development of a nitric oxide-releasing analogue of the muscle relaxant guaifenesin for skeletal muscle satellite cell myogenesis. Mol Pharm. 2009 May-Jun; 6(3):895-904. [PMID: 19317416]
Wang GQ, Gong YW, and Burczynski FJ. Expression and antioxidant function of liver fatty acid binding protein in normal and bile-duct ligated rats. Eur J Pharmacol 2007; 560: 61-68. [PMID: 17292345]
Wang GQ, Wang J, Burczynski FJ, and Zhong GM. Effect of fatty acid binding protein on Chlamydia Trachomatis L2. Microbiology 2007; 153:1935-1939. [PMID: 17526850]
Wang GQ, Gong YW, Anderson J, Sun D, Minuk GY, and Burczynski FJ. Antioxidative Function of L-FABP in L-FABP Stable Transfected Chang Liver Cells. Hepatology 2005; 42: 871-879. [PMID: 16175609]